Art

J-GLOBAL ID：201002248134992314   Reference number：10A0874871

New Approaches to Blockade of the Renin-Angiotensin-Aldosterone System: Characteristics and Usefulness of the Direct Renin Inhibitor Aliskiren

レニン-アンギオテンシン-アルドステロン系の遮断への新たなアプローチ:直接的レニン阻害剤アリスキレンの特性と有用性

Author (7)： ICHIHARA Atsuhiro (Departments of Anti-Aging Medicine & Endocrinology and Internal Medicine, Keio Univ. School of Medicine, JPN) ,  SAKODA Mariyo (Departments of Anti-Aging Medicine & Endocrinology and Internal Medicine, Keio Univ. School of Medicine, JPN) ,  KURAUCHI-MITO Asako (Departments of Anti-Aging Medicine & Endocrinology and Internal Medicine, Keio Univ. School of Medicine, JPN) ,  NARITA Tatsuya (Departments of Anti-Aging Medicine & Endocrinology and Internal Medicine, Keio Univ. School of Medicine, JPN) ,  KINOUCHI Kenichiro (Departments of Anti-Aging Medicine & Endocrinology and Internal Medicine, Keio Univ. School of Medicine, JPN) ,  BOKUDA Kanako (Departments of Anti-Aging Medicine & Endocrinology and Internal Medicine, Keio Univ. School of Medicine, JPN) ,  ITOH Hiroshi (Departments of Anti-Aging Medicine & Endocrinology and Internal Medicine, Keio Univ. School of Medicine, JPN)
Material： Journal of Pharmacological Sciences  (J Pharmacol Sci)
Volume： 113  Issue： 4  Page： 296-300 (J-STAGE)  Publication year： 2010 
JST Material Number： G0813A  ISSN： 1347-8613  Document type： Article
Article type： 解説  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： *enzyme inhibitor ,...
Semi thesaurus term： ACE-inhibitor ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=10A0874871&from=J-GLOBAL&jstjournalNo=G0813A") }}

JST classification (3)： Clinical application of vasoactive drugs and hypotensive drugs  (GW07050U) ,  Drug therapy(=pharmacotherapy)for cardiovascular system diseases  (GJ05020M) ,  Clinical application of enzyme preparations and inhibitor preparations  (GW21020H)

Substance index (2)： Amlodipine ,  Aliskiren

Reference (22)：

• 1 Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004;25:292–299.
• 2 Wood JM, Stanton JL, Hofbauer KG. Inhibitors of renin as potential therapeutic agents. J Enzyme Inhib. 1987;1:169–185.
• 3 Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen N-C, Rasetti V, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003;308:698–705.
• 4 Palatini P, Jung W, Shlyakhto W, Botha J, Bush C, Keefe DL. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irebesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens. 2009;24:93–103.
• 5 Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension. 2008;52:130–136.

Terms in the title (5)： レニン-アンギオテンシン-アルドステロン系 ,  遮断 ,  直接的レニン阻害剤 ,  アリスキレン ,  有用性